FDA Extends Agilect User Fee Deadline Due To “Technical Error”
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is extending the user fee deadline for Teva's Parkinson's disease agent Agilect (rasagiline) by three months following the firm's submission of additional data to clarify a "technical error.
You may also be interested in...
Eisai To Resubmit Aricept Severe Alzheimer’s sNDA In December
Firm is considering changing from paper to electronic filing to resolve formatting issues behind FDA’s refusal to file the sNDA.
Eisai To Resubmit Aricept Severe Alzheimer’s sNDA In December
Firm is considering changing from paper to electronic filing to resolve formatting issues behind FDA’s refusal to file the sNDA.
Avanir Neurodex NDA Delayed By FDA Request For Additional Analyses
Agency requested new summary analyses "to better support the new electronic data submission guidelines," the company says.